Home » Stocks » Genocea Biosciences

Genocea Biosciences, Inc. (GNCA)

Stock Price: $3.12 USD -0.06 (-1.89%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $3.15 +0.03 (0.96%) Aug 4, 7:13 PM

Stock Price Chart

Key Info

Market Cap 93.49M
Revenue (ttm) 906,000
Net Income (ttm) -41.06M
Shares Out 29.96M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $3.12
Previous Close $3.18
Change ($) -0.06
Change (%) -1.89%
Day's Open 3.10
Day's Range 2.88 - 3.30
Day's Volume 1,634,773
52-Week Range 1.10 - 5.75

More Stats

Market Cap 93.49M
Enterprise Value 95.90M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.96M
Float 11.24M
EPS (basic) -1.4
EPS (diluted) -1.47
FCF / Share -1.53
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 231,511
Short Ratio 0.61
Short % of Float 1.51%
Beta 2.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 103.19
PB Ratio 11.64
Revenue 906,000
Operating Income -43.98M
Net Income -41.06M
Free Cash Flow -44.48M
Net Cash -2.41M
Net Cash / Share -0.08
Gross Margin -2,974.83%
Operating Margin -4,854.53%
Profit Margin -4,532.20%
FCF Margin -4,909.93%
ROA -49.41%
ROE -176.71%
ROIC -165.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$9.40*
(201.28% upside)
Low
5.00
Current: $3.12
High
18.00
Target: 9.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue---0.240.670.310.731.981.82
Revenue Growth----64.93%117.53%-57.87%-63.02%8.63%-
Gross Profit---0.240.670.310.731.981.82
Operating Income-38.99-39.52-55.26-48.25-41.37-33.17-19.93-12.95-14.73
Net Income-38.95-27.81-56.71-49.57-42.48-35.30-20.81-13.37-14.69
Shares Outstanding20.6410.323.583.543.061.950.040.040.04
Earnings Per Share-1.89-2.69-15.84-14.00-13.92-18.16-603.68-410.80-443.28
Operating Cash Flow-37.73-41.24-47.60-41.84-38.36-27.60-19.87-12.68-13.49
Capital Expenditures-1.09-0.13-1.03-2.54-2.78-1.52-0.39-0.46-0.32
Free Cash Flow-38.82-41.37-48.63-44.37-41.14-29.12-20.26-13.14-13.81
Cash & Equivalents40.7626.6812.5963.6894.6447.4012.5211.935.84
Total Debt19.9214.8214.3116.9616.4811.399.794.050.21
Net Cash / Debt20.8411.86-1.7246.7278.1736.012.737.885.63
Assets52.6131.1217.4969.9011250.3315.7613.536.94
Liabilities27.5723.7823.5424.3622.4817.8314.337.232.65
Book Value25.047.34-6.0545.5489.6632.51-80.13-58.40-43.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Genocea Biosciences, Inc.
Country United States
Employees 59
CEO William D. Clark

Stock Information

Ticker Symbol GNCA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GNCA
IPO Date February 5, 2014

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.